Baxter International Inc
BAX: XNYS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| &C | LOCK|VXTnl | LOCK|!G% |
Baxter's Intermediate-Term Outlook Looks Highly Uncertain
Business Strategy and Outlook
Although the 2015 Baxalta spinoff was successful, Baxter's financial results fell substantially in 2022-23 on external pressures, such as inflation and weak medical utilization trends. With medical utilization rising, supply chain pressures easing, and new contracts with group purchasing organizations coming online, Baxter's profits remain in turnaround mode.
